Aptus Pharma (BOM:544529) Beneish M-Score: 1.26 (As of Jul. 31, 2026) — 2420% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544529 Aptus Pharma Ltd BOM:544529
18 GF Score
Price ₹269.50
! 6 Warning Signs
View Full Analysis

What is Aptus Pharma Beneish M-Score?

Aptus Pharma BOM:544529 +3.63% 18 Beneish M-Score is 1.26 as of Jul. 31, 2026, which is 2420% above its 10-year median of 0.05. GuruFocus rates BOM:544529 with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 116 Medical Distribution companies, Aptus Pharma ranks worse than 96.55% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 1.26 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Aptus Pharma's Beneish M-Score or its related term are showing as below:

BOM:544529' s Beneish M-Score Range Over the Past 10 Years
Min: -1.16   Med: 0.05   Max: 1.26
Current: 1.26

During the past 4 years, the highest Beneish M-Score of Aptus Pharma was 1.26. The lowest was -1.16. And the median was 0.05.

Aptus Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Aptus Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptus Pharma Beneish M-Score Chart

Aptus Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Beneish M-Score
0.00 0.00 -1.16 1.26

Aptus Pharma Semi-Annual Data
Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial 0.00 0.00 -1.16 0.00 1.26

BOM:544529 vs MCK, COR, CAH: Beneish M-Score Comparison

For the Medical Distribution subindustry, Aptus Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptus Pharma Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Aptus Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aptus Pharma's Beneish M-Score falls into.


BOM:544529
18GF Score
Aptus Pharma Ltd BOM:544529
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptus Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aptus Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.8036+0.528 * 1.1679+0.404 * 2.3032+0.892 * 1.8965+0.115 * 1.6435
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.263688-0.327 * 0.6789
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹205.6 Mil.
Revenue was ₹465.7 Mil.
Gross Profit was ₹252.0 Mil.
Total Current Assets was ₹352.4 Mil.
Total Assets was ₹435.3 Mil.
Property, Plant and Equipment(Net PPE) was ₹27.1 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹4.1 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0.0 Mil.
Total Current Liabilities was ₹193.1 Mil.
Long-Term Debt & Capital Lease Obligation was ₹5.2 Mil.
Net Income was ₹46.2 Mil.
Gross Profit was ₹0.0 Mil.
Cash Flow from Operations was ₹-68.6 Mil.
 Total Receivables was ₹60.1 Mil.
Revenue was ₹245.6 Mil.
Gross Profit was ₹155.2 Mil.
Total Current Assets was ₹197.4 Mil.
Total Assets was ₹219.2 Mil.
Property, Plant and Equipment(Net PPE) was ₹9.6 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹2.6 Mil.
Selling, General, & Admin. Expense(SGA) was ₹48.8 Mil.
Total Current Liabilities was ₹120.8 Mil.
Long-Term Debt & Capital Lease Obligation was ₹26.2 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(205.551 / 465.746) / (60.091 / 245.577)
=0.441337 / 0.244693
=1.8036

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(155.208 / 245.577) / (252.048 / 465.746)
=0.632014 / 0.541171
=1.1679

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (352.362 + 27.141) / 435.348) / (1 - (197.361 + 9.63) / 219.199)
=0.128277 / 0.055694
=2.3032

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=465.746 / 245.577
=1.8965

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.634 / (2.634 + 9.63)) / (4.08 / (4.08 + 27.141))
=0.214775 / 0.130681
=1.6435

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 465.746) / (48.844 / 245.577)
=0 / 0.198895
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.216 + 193.058) / 435.348) / ((26.204 + 120.836) / 219.199)
=0.455438 / 0.670806
=0.6789

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(46.199 - 0 - -68.597) / 435.348
=0.263688

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aptus Pharma has a M-score of 1.26 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 1.26 mean?
Aptus Pharma (BOM:544529) has a Beneish M-Score of 1.26 as of Jul. 31, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aptus Pharma and its competitors. This is 2420% above median its historical median of 0.05. According to the industry distribution chart, Aptus Pharma ranks #112 out of 116 companies in the Medical Distribution industry, placing it in the top 96.6%.
Is Aptus Pharma's Beneish M-Score too high?
Aptus Pharma's current Beneish M-Score of 1.26 is 2420% above median its 10-year median of 0.05. Based on the distribution chart, Aptus Pharma ranks #112 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's Beneish M-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Aptus Pharma ranks #112 out of 116 companies for Beneish M-Score. This places Aptus Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Distribution company?
A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aptus Pharma and its competitors. Aptus Pharma's current Beneish M-Score is 1.26, which is 2420% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current Beneish M-Score of 1.26. The current Beneish M-Score is 1.26, which is 2420% above median its 10-year median of 0.05. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current Beneish M-Score is 1.26 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptus Pharma Business Description

Address Narayan Nagar, Kalawad Road, SHREE Building, 1st Floor, Opp Satyasai Heart Hospital, Sau Uni Area, Rajkot, GJ, IND, 360005
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score

Get the complete analysis for BOM:544529

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹269.50
Price